Vascular endothelial growth factor receptor 3

BE0000023ProteinHumansFLT4

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. It is acted on by 26 drugs in DrugBank.

Gene name
FLT4
UniProtKB entry
P35916Swiss-Prot
Cellular location
Cell membrane
Residues / weight
1,363 residues · 152,756 Da
Also known as
2.7.10.1 · FLT-4 · Fms-like tyrosine kinase 4 · Tyrosine-protein kinase receptor FLT4 · VEGFR-3

Resolves to

Protein
UniProtP35916UniProt nameVGFR3_HUMAN
Gene
HGNCHGNC:3767NCBI Gene2324GenBank297050GeneCardsFLT4
Pharmacology
IUPHAR/GtoPdb1814KEGGhsa:2324
Structure
PDB4BSJPDB4BSK
Drugs

What you can answer from here — as of September 07, 2019

26DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
49Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
9GO termsFunction, process and component, as structured annotations
Sign in
7Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
116+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Vascular endothelial growth factor receptor 3, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In